ArticleMethods in molecular biology (Clifton, N.J.)2026
Systematic Production of IgG-Like Bispecific Antibodies via Intein-Mediated Protein Trans-Splicing.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bispecific antibodies show therapeutic potential; thus, their screening campaign has attracted attention for the development of biotherapeutics. However, many bispecific formats require engineering or fine-tuned purification processes optimized for each molecule, hindering simple screening, especially when impurities are not allowed. In this chapter, we describe a method for producing IgG-like bispecific antibodies via intein-mediated protein trans-splicing, fusing two polypeptide units post-translationally. This method allows the separate expression of two antigen-binding fragments and eliminates the light chain problem. Homobivalent species are not contaminated. In addition, the common purification process finalized by size-exclusion chromatography enables the systematic production of bispecific antibodies suitable for in vitro screening.
Indexed as
Identifiers
42129102What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.